Private Wealth Partners LLC Boosts Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Private Wealth Partners LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 85,131 shares of the medical research company’s stock after purchasing an additional 815 shares during the period. Thermo Fisher Scientific comprises about 3.8% of Private Wealth Partners LLC’s investment portfolio, making the stock its 6th largest position. Private Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $45,187,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Thermo Fisher Scientific by 0.6% in the third quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock worth $16,582,503,000 after acquiring an additional 180,618 shares during the period. Morgan Stanley lifted its position in shares of Thermo Fisher Scientific by 0.4% during the third quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock valued at $6,285,838,000 after buying an additional 50,736 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Thermo Fisher Scientific by 2.6% during the third quarter. Northern Trust Corp now owns 3,929,225 shares of the medical research company’s stock valued at $1,988,856,000 after acquiring an additional 99,377 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Thermo Fisher Scientific by 9.8% during the third quarter. Wellington Management Group LLP now owns 3,080,687 shares of the medical research company’s stock valued at $1,559,351,000 after acquiring an additional 274,464 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Thermo Fisher Scientific by 0.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,184,928 shares of the medical research company’s stock valued at $1,105,945,000 after acquiring an additional 8,672 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded up $1.87 during midday trading on Friday, hitting $573.60. The stock had a trading volume of 1,438,184 shares, compared to its average volume of 1,317,052. The company has a market capitalization of $218.95 billion, a PE ratio of 36.79, a P/E/G ratio of 2.42 and a beta of 0.80. The stock has a 50 day simple moving average of $573.60 and a 200-day simple moving average of $530.14. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.70 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Wall Street Analyst Weigh In

TMO has been the topic of several recent analyst reports. Royal Bank of Canada upped their price objective on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Robert W. Baird cut their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday. Evercore ISI increased their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Raymond James increased their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $606.76.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.